4.2 Review

Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis

Related references

Note: Only part of the references are listed.
Editorial Material Hematology

Perspective: SARS-CoV-2, COVID-19 and Haematologists

Robert Peter Gale

ACTA HAEMATOLOGICA (2021)

Article Surgery

COVID-19 in transplant recipients: The Spanish experience

Elisabeth Coll et al.

Summary: This study reported the experience of solid organ and hematopoietic stem cell transplant recipients diagnosed with COVID-19 in Spain until July 13, 2020. The incidence of COVID-19 in transplant recipients was higher than the general population. Most patients required hospitalization, and adjusting immunosuppression could improve survival rates. Risk factors for death included age, lung transplantation, and hospital-acquired COVID-19.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Article Hematology

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Akshay Sharma et al.

Summary: This study examined the characteristics and outcomes of HSCT recipients after developing COVID-19. It found that recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival rates. Factors such as age, sex, and time since transplantation were associated with higher risk of mortality in HSCT recipients.

LANCET HAEMATOLOGY (2021)

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Article Biophysics

Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East

Riad El Fakih et al.

Summary: The study analyzed the clinical outcomes of post-HCT patients who contracted COVID-19 in the Middle East. The results showed overall favorable clinical outcomes for patients, with those having more than 6 months from HCT to COVID-19 exhibiting lower admission rates and severity composite endpoint rates.

BONE MARROW TRANSPLANTATION (2021)

Article Immunology

Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy

Jose F. Camargo et al.

Summary: Mortality in COVID-19 HCT patients is higher than the age-comparable general population, largely dependent on factors such as age, disease severity, timing from HCT, and intensity of immunosuppression.

TRANSPLANT INFECTIOUS DISEASE (2021)

Article Oncology

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

P. Grivas et al.

Summary: This study analyzed clinical factors and laboratory measurements of cancer patients with COVID-19, finding that factors such as age, sex, comorbidities, cancer type, and laboratory results were associated with COVID-19 severity. Patients diagnosed early in the pandemic had worse outcomes, and specific anticancer therapies may increase 30-day all-cause mortality. More research is needed to confirm these findings and caution may be needed in using certain anticancer treatments.

ANNALS OF ONCOLOGY (2021)

Article Oncology

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Per Ljungman et al.

Summary: The study reveals that COVID-19 patients who have undergone allogeneic or autologous hematopoietic cell transplantation are at high risk of developing lower respiratory tract disease, requiring ICU admission, and have increased mortality rates.

LEUKEMIA (2021)

Article Oncology

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson et al.

Summary: This study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19. Results showed that convalescent plasma treatment was associated with improved 30-day mortality, especially in patients requiring intensive care unit admission or mechanical ventilatory support.

JAMA ONCOLOGY (2021)

Article Immunology

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Zachary A. Yetmar et al.

Summary: This study retrospectively reviewed solid organ transplant recipients who received monoclonal antibody treatment for COVID-19, showing favorable outcomes and minimal adverse effects in this patient population. Early administration of monoclonal antibody therapy appears to be more efficacious.

OPEN FORUM INFECTIOUS DISEASES (2021)

Article Medicine, General & Internal

Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19

Michael E. Ohl et al.

Summary: This study examined the association between remdesivir treatment and survival as well as length of hospital stay among COVID-19 patients. The results showed that remdesivir treatment was not associated with improved survival but was linked to longer hospital stays.

JAMA NETWORK OPEN (2021)

Article Hematology

Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients

Muhammad Umair Mushtaq et al.

Summary: This study investigated the impact of SARS-CoV-2 in HCT/CAR-T therapy recipients, finding that these patients have a higher risk of mortality. The primary hematologic disorders included plasma cell, myeloid, and lymphoid malignancies. 50% of COVID-19 patients had mild severity, 22% had moderate, and 28% had severe severity.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Article Biophysics

COVID-19 in hematopoietic cell transplant recipients

Fevzi Altuntas et al.

Summary: This study reports the outcomes of COVID-19 in hematopoietic cell transplant recipients, showing a higher case fatality rate in these patients, particularly among those receiving immunosuppressive agents.

BONE MARROW TRANSPLANTATION (2021)

Letter Biophysics

The outcome of hematopoietic stem cell transplantation patients with COVID-19 infection

Almetwaly M. Sultan et al.

BONE MARROW TRANSPLANTATION (2021)

Review Immunology

T cell regeneration after immunological injury

Enrico Velardi et al.

Summary: This article discusses the importance of immune reconstitution, specifically of T cells, following periods of haematopoietic cell stress. Delayed or defective recovery of T cells can have significant clinical consequences, highlighting the need for therapeutic strategies to restore immune function.

NATURE REVIEWS IMMUNOLOGY (2021)

Article Medicine, General & Internal

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients

Ayse Karatas et al.

Summary: This study retrospectively analyzed the clinical course and outcomes of COVID-19 patients who had undergone hematopoietic stem cell transplantation, finding that factors such as baseline characteristics, hospitalization rates, and mortality were related to the patients' conditions before transplantation. Further studies with larger sample sizes are needed to fully understand the effects of COVID-19 on HSCT patients.

TURKISH JOURNAL OF MEDICAL SCIENCES (2021)

Article Immunology

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Zachary A. Yetmar et al.

Summary: Monoclonal antibody therapy for COVID-19 appears to be safe and effective with favorable outcomes in solid organ transplant recipients, with earlier administration associated with reduced hospitalizations. No episodes of rejection or anaphylaxis were reported.

OPEN FORUM INFECTIOUS DISEASES (2021)

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Letter Biophysics

COVID-19 outcomes in patients with hematologic disease

Florent Malard et al.

BONE MARROW TRANSPLANTATION (2020)

Letter Hematology

COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience

Alexandros Kanellopoulos et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Editorial Material Immunology

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Meijuan Zheng et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Letter Respiratory System

Association between age and clinical characteristics and outcomes of COVID-19

Yang Liu et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Editorial Material Oncology

Hematopoietic stem cell transplantation dilemma during the COVID-19 era

Ramy Samaha et al.

FUTURE ONCOLOGY (2020)

Review Nutrition & Dietetics

COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation

Ioannis Zabetakis et al.

NUTRIENTS (2020)

Letter Medicine, General & Internal

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?

Andrew I. Ritchie et al.

LANCET (2020)

Article Medicine, General & Internal

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Hematology

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

Alpana Waghmare et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Article Medicine, General & Internal

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial

Christoph D. Spinner et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Editorial Material Medicine, General & Internal

A living WHO guideline on drugs for covid-19

Francois Lamontagne et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Article Oncology

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Jose Luis Pinana et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)

Article Medicine, Research & Experimental

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Gunjan L. Shah et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Letter Medicine, General & Internal

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Ning Rosenthal et al.

JAMA NETWORK OPEN (2020)

Article Health Care Sciences & Services

Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data

Zachary Munn et al.

INTERNATIONAL JOURNAL OF EVIDENCE-BASED HEALTHCARE (2015)